State of New Jersey Common Pension Fund D grew its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,506 shares of the medical research company's stock after purchasing an additional 6,879 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Bruker were worth $2,550,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its position in shares of Bruker by 51.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,761 shares of the medical research company's stock worth $14,555,000 after acquiring an additional 71,275 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Bruker by 3.8% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 34,172 shares of the medical research company's stock worth $2,360,000 after purchasing an additional 1,251 shares during the period. Values First Advisors Inc. purchased a new position in Bruker during the third quarter worth approximately $73,000. Louisiana State Employees Retirement System grew its holdings in Bruker by 11.3% in the third quarter. Louisiana State Employees Retirement System now owns 30,600 shares of the medical research company's stock valued at $2,113,000 after purchasing an additional 3,100 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Bruker by 109.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 13,110 shares of the medical research company's stock valued at $905,000 after buying an additional 6,863 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on BRKR. Bank of America lifted their price target on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. The Goldman Sachs Group raised shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price for the company in a research note on Thursday, December 5th. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Friday, January 17th. Wells Fargo & Company cut their price objective on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Finally, TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a report on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bruker currently has an average rating of "Moderate Buy" and a consensus price target of $70.50.
View Our Latest Stock Report on BRKR
Bruker Trading Down 4.0 %
Shares of NASDAQ BRKR traded down $2.10 during trading on Friday, reaching $50.82. The stock had a trading volume of 2,050,917 shares, compared to its average volume of 1,650,530. The business's 50-day moving average price is $56.87 and its 200-day moving average price is $60.13. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market cap of $7.70 billion, a P/E ratio of 66.87, a PEG ratio of 2.10 and a beta of 1.16.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, equities research analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
